News

Filter events

  • Research | 11.03.2014

    Inauguration of a Regional Platform of Research on transmissible and emerging infectious diseases in Southeast Asia (PRR-Asia)

    Southeast Asia (SEA) is affected by emerging infectious diseases, and emerging outbreaks challenge the medical and scientific communities. The emergence of new diseases or their resistance to anti-microbial drugs in SEA is a complex mechanism which requires more interest on the diseases, on the condition of their emergence and on the diffusion of the causative agents. The study of infection transmitted or not by animals or arthropod vectors involves a new interdisciplinary approach with systemic and transversal collaborations between teams and institutions on priority programs integrated into a global health international strategy.

    The implementation of a Regional Platform of Research-Asia (PRR-Asia) in the campus of Institute Pasteur in Cambodia (IPC) will offer a unique opportunity for research teams from the North and the South to share their regional and international expertise and to develop strong partnerships through multi-sectoral research programs complementary to ongoing research on infectious diseases in relation with IPC and its partners.

  • Research | 17.01.2014

    A new bacterial mechanism for evading the immune system

    A team of scientists from the Institut Pasteur, the CNRS and Paris Diderot University has identified a new regulation mechanism that enables a pathogenic bacterium of the Streptococcus genus to rapidly adapt to its host. This study was published on January 16, 2014 in PLoS Pathogens. The mechanism in question enables the bacterium to minimize its exposure to the immune system while maintaining effective tissue colonization. This work was carried out on Streptococcus gallolyticus, an intestinal tract bacterium responsible for endocarditis and septicemia in the elderly.

  • Research | 19.12.2013

    Molecular marker discovered for detecting artemisinin-resistant forms of malaria

    Scientists at the Institut Pasteur in Paris and Cambodia, CNRS and NIH have identified a molecular marker for detecting malaria parasites with resistance to artemisinin derivatives

    Un marqueur moléculaire permettant de détecter les parasites du paludisme résistants aux dérivés de l’artémisinine, constituants majeurs des traitements antipaludiques actuellement recommandés par l’OMS, a été identifié par des scientifiques de l’Institut Pasteur à Paris, de l’Institut Pasteur du Cambodge, du CNRS et des National Institutes of Health (NIAID/NIH).

  • Research | 13.12.2013

    A prime target for the development of anti-inflammatories

    For the first time, scientists from the Institut Pasteur and Inserm have demonstrated the key role played by a particular molecule in intestinal infection.

  • Research | 12.12.2013

    Carriers of a genetic mutation show increased dependence on tobacco

    Scientists at the Institut Pasteur, the French National Center for Scientific Research (CNRS) and Pierre and Marie Curie University (UPMC) have recently proven that, in mice, nicotine intake – nicotine is the main addictive substance in tobacco – is heavily regulated by a genetic mutation that is very common in humans. 

  • Research | 28.11.2013

    Clinical trial launched to treat Sanfilippo B syndrome using gene therapy

    A phase I/II gene therapy clinical trial for children suffering from Sanfilippo B syndrome, a rare genetic disease, enrolled a first patient in October of this year. The trial is being carried out and coordinated by the Institut Pasteur (the trial’s sponsor), Inserm, AFM-Téléthon and Vaincre les Maladies Lysosomales (VML). It is being conducted at Bicêtre Hospital (AP-HP) in Paris. If the treatment is successful it will pave the way towards the development of other gene therapy treatments using the same process.

  • Research | 05.11.2013

    Two European programs reinforce the fight against emerging diseases

    The 31 partners involved in the two major European research programs PREDEMICS and ANTIGONE are to meet for a joint seminar at the Institut Pasteur on November 6th. These two programs will respectively receive €11.7 million and €12 million funding of the European Union over five years to study the emergence mechanisms of infectious diseases in order to strengthen existing treatment and prevention. Since their launch, PREDEMICS and ANTIGONE have been active in various areas, in particular for modeling the spread and evolution of emerging pathogens and for studying host-pathogen interactions.

  • Research | 04.11.2013

    Identification of a new mechanism in immunotherapy for lymphoma

    Using innovative dynamic imaging technique, scientists at the Institut Pasteur, Inserm and the VU Medical Center in Amsterdam have uncovered the mode of action of anti-CD20, an antibody therapy frequently used in the treatment of lymphomas (cancers of the immune system) as well as some auto-immune diseases. In a lymphoma model, the scientists have been able to carry out real time in vivo imaging of the cellular events activated by the treatment and resulting in the destruction of tumor cells. These discoveries should help optimize the efficacy of future therapies involving anti-CD20 antibodies. This work is the subject of an article published online November 1 on the Journal of Clinical Investigation website.

  • Research | 10.10.2013

    Fine-tuning the approach to malaria and toxoplasmosis research

    A study carried out by teams from the Institut Pasteur, the Institut Cochin (Inserm, CNRS, Paris Descartes University), and the Wellcome Trust Centre for Molecular Parasitology at the University of Glasgow, may very well redefine current approaches to malaria and toxoplasmosis research in terms of treatment development. Their research which focuses on the role played by the protein AMA1 (present in both parasites) was published october 9, on the Nature Communications website. For many years AMA1 has been the focus of studies aiming to develop malaria treatments and vaccines. However, the authors of this study express their reservations about strategies that focus strictly on blocking AMA1 and show that malaria and toxoplasmosis parasites without AMA1 are still capable of developing normally.

  • Research | 01.10.2013

    Potential therapeutic targets for blocking AIDS virus replication

    Scientists from the Institut Pasteur and Inserm have identified several proteins in humans as potential new therapeutic targets for treating the AIDS virus. These proteins are part of a complex cellular mechanism that blocks the virus replication in cells called macrophages. The discovery of this mechanism and the proteins involved gives scientists a solid theoretical basis for developing new therapeutic strategies to be used alongside anti-retroviral treatments currently in use. This research was published online September 30, 2013 by the scientific journal Proceedings of the National Academy of Sciences.

donation_form_widget.jpg

Zoom in on...

Pasteur museum

Welcome to Pasteur Museum


musee-institut-pasteur.jpg


The Pasteur Museum is located at the Institut Pasteur, situated at: 25 rue du Docteur Roux 75015 Paris, France
 

Pasteur Museum